T

wo weeks ago, Merck (MRKpleasantly surprised investors by releasing promising top-line findings of a key lung cancer study for its Keytruda medicine. But a new survey suggests that some doctors remain squeamish about using the drug as a first-line treatment for their patients.

Specifically, 56 percent of 32 oncologists who were surveyed found the results encouraging, but are waiting for the complete study data to be released before they may use Keytruda as a first-line treatment, according to Bernstein analyst Tim Anderson, who commissioned the survey.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Father diagnosed with stage 4 lung cancer. PDL1 markers greater than 90%. May 11, 2017. Keytruda 200mg every 3 weeks. Passed away October 2, 2017. Did not work.

  • I have been on Keytruda every 21 days sice March 2017…i had lung cancer in both lungs. I am staying on Keytruda until spring for precautions but my cancer is gone. My doctor said i am a walking miracle!! I believe in Keytruda!!!

  • Mother 82, stage 4. Last January was lucky enough to take part in trial. Fox Chase suggested Kytruda. This Jan. Tumor has shrunk 2.8 to 1.1. No side effects. Tell everyone I know about this promising treatment. Thank you Merck.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.